185 related articles for article (PubMed ID: 31863416)
1. Regional Node Basin Recurrence in Melanoma Patients: More Common After Node Dissection for Macroscopic Rather than Clinically Occult Nodal Disease.
Uppal A; Stern S; Thompson JF; Foshag L; Mizzollo N; Nieweg OE; Hoekstra HJ; Roses DF; Sondak VK; Kashani-Sabet M; Coventry BJ; Cochran AJ; Fujita M; Sim-Shin M; Elashoff D; Elashoff RM; Faries MB
Ann Surg Oncol; 2020 Jun; 27(6):1970-1977. PubMed ID: 31863416
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic Value of Sentinel Lymph Node Biopsy in Patients With Melanoma: A Randomized Clinical Trial.
; Crystal JS; Thompson JF; Hyngstrom J; Caracò C; Zager JS; Jahkola T; Bowles TL; Pennacchioli E; Beitsch PD; Hoekstra HJ; Moncrieff M; Ingvar C; van Akkooi A; Sabel MS; Levine EA; Agnese D; Henderson M; Dummer R; Neves RI; Rossi CR; Kane JM; Trocha S; Wright F; Byrd DR; Matter M; Hsueh EC; MacKenzie-Ross A; Kelley M; Terheyden P; Huston TL; Wayne JD; Neuman H; Smithers BM; Ariyan CE; Desai D; Gershenwald JE; Schneebaum S; Gesierich A; Jacobs LK; Lewis JM; McMasters KM; O'Donoghue C; van der Westhuizen A; Sardi A; Barth R; Barone R; McKinnon JG; Slingluff CL; Farma JM; Schultz E; Scheri RP; Vidal-Sicart S; Molina M; Testori AAE; Foshag LJ; Van Kreuningen L; Wang HJ; Sim MS; Scolyer RA; Elashoff DE; Cochran AJ; Faries MB
JAMA Surg; 2022 Sep; 157(9):835-842. PubMed ID: 35921122
[TBL] [Abstract][Full Text] [Related]
3. Observation after a positive sentinel lymph node biopsy in patients with melanoma.
Bamboat ZM; Konstantinidis IT; Kuk D; Ariyan CE; Brady MS; Coit DG
Ann Surg Oncol; 2014 Sep; 21(9):3117-23. PubMed ID: 24833100
[TBL] [Abstract][Full Text] [Related]
4. International multi-institutional management and outcome of melanoma patients with positive sentinel lymph nodes in more than one nodal basin.
Melstrom LG; Taylor E; Kuk D; Frankel TL; Panageas K; Haydu L; Sabel MS; Thompson JF; Ariyan C; Coit DG; Brady MS
Ann Surg Oncol; 2014 Dec; 21(13):4324-9. PubMed ID: 24962937
[TBL] [Abstract][Full Text] [Related]
5. Surveillance of Sentinel Node-Positive Melanoma Patients with Reasons for Exclusion from MSLT-II: Multi-Institutional Propensity Score Matched Analysis.
Broman KK; Hughes TM; Dossett LA; Sun J; Carr MJ; Kirichenko DA; Sharma A; Bartlett EK; Nijhuis AA; Thompson JF; Hieken TJ; Kottschade L; Downs J; Gyorki DE; Stahlie E; van Akkooi A; Ollila DW; Frank J; Song Y; Karakousis G; Moncrieff M; Nobes J; Vetto J; Han D; Farma J; Deneve JL; Fleming MD; Perez M; Baecher K; Lowe M; Bagge RO; Mattsson J; Lee AY; Berman RS; Chai H; Kroon HM; Teras RM; Teras J; Farrow NE; Beasley GM; Hui JY; Been L; Kruijff S; Boulware D; Sarnaik AA; Sondak VK; Zager JS;
J Am Coll Surg; 2021 Apr; 232(4):424-431. PubMed ID: 33316427
[TBL] [Abstract][Full Text] [Related]
6. Nodal basin recurrence following lymph node dissection for melanoma: implications for adjuvant radiotherapy.
Lee RJ; Gibbs JF; Proulx GM; Kollmorgen DR; Jia C; Kraybill WG
Int J Radiat Oncol Biol Phys; 2000 Jan; 46(2):467-74. PubMed ID: 10661355
[TBL] [Abstract][Full Text] [Related]
7. Sentinel lymph node biopsy followed by lymph node dissection for localised primary cutaneous melanoma.
Kyrgidis A; Tzellos T; Mocellin S; Apalla Z; Lallas A; Pilati P; Stratigos A
Cochrane Database Syst Rev; 2015 May; 2015(5):CD010307. PubMed ID: 25978975
[TBL] [Abstract][Full Text] [Related]
8. Active surveillance of patients who have sentinel node positive melanoma: An international, multi-institution evaluation of adoption and early outcomes after the Multicenter Selective Lymphadenectomy Trial II (MSLT-2).
Broman KK; Hughes T; Dossett L; Sun J; Kirichenko D; Carr MJ; Sharma A; Bartlett EK; Nijhuis AAG; Thompson JF; Hieken TJ; Kottschade L; Downs J; Gyorki DE; Stahlie E; van Akkooi A; Ollila DW; Frank J; Song Y; Karakousis G; Moncrieff M; Nobes J; Vetto J; Han D; Farma JM; Deneve JL; Fleming MD; Perez MC; Lowe MC; Olofsson Bagge R; Mattsson J; Lee AY; Berman RS; Chai H; Kroon HM; Teras J; Teras RM; Farrow NE; Beasley G; Hui JYC; Been L; Kruijff S; Kim Y; Naqvi SMH; Sarnaik AA; Sondak VK; Zager JS
Cancer; 2021 Jul; 127(13):2251-2261. PubMed ID: 33826754
[TBL] [Abstract][Full Text] [Related]
9. Survival analysis and clinicopathological factors associated with false-negative sentinel lymph node biopsy findings in patients with cutaneous melanoma.
Nowecki ZI; Rutkowski P; Nasierowska-Guttmejer A; Ruka W
Ann Surg Oncol; 2006 Dec; 13(12):1655-63. PubMed ID: 17016755
[TBL] [Abstract][Full Text] [Related]
10. Nodal Basin Recurrence After Sentinel Lymph Node Biopsy for Melanoma: A Retrospective Multicenter Study in 2653 Patients.
Kretschmer L; Bertsch HP; Zapf A; Mitteldorf C; Satzger I; Thoms KM; Völker B; Schön MP; Gutzmer R; Starz H
Medicine (Baltimore); 2015 Sep; 94(36):e1433. PubMed ID: 26356697
[TBL] [Abstract][Full Text] [Related]
11. Management of Sentinel Lymph Node Metastasis in Merkel Cell Carcinoma: Completion Lymphadenectomy, Radiation, or Both?
Perez MC; Oliver DE; Weitman ES; Boulware D; Messina JL; Torres-Roca J; Cruse CW; Gonzalez RJ; Sarnaik AA; Sondak VK; Wuthrick EJ; Harrison LB; Zager JS
Ann Surg Oncol; 2019 Feb; 26(2):379-385. PubMed ID: 30311164
[TBL] [Abstract][Full Text] [Related]
12. In transit/local recurrences in melanoma patients after sentinel node biopsy and therapeutic lymph node dissection.
Rutkowski P; Nowecki ZI; Zurawski Z; Dziewirski W; Nasierowska-Guttmejer A; Switaj T; Ruka W
Eur J Cancer; 2006 Jan; 42(2):159-64. PubMed ID: 16324835
[TBL] [Abstract][Full Text] [Related]
13. Multicenter Adoption and Outcomes of Nodal Observation for Patients with Melanoma and Sentinel Lymph Node Metastases.
Parvez E; Khosrow-Khavar F; Dumitra T; Nessim C; Bernard-Bédard É; Rivard J; Pravong V; Wang S; Gervais MK; Meterissian S; Dumitra S
Ann Surg Oncol; 2023 Feb; 30(2):1195-1205. PubMed ID: 36282456
[TBL] [Abstract][Full Text] [Related]
14. Prediction of Residual Nodal Disease at Completion Dissection Following Positive Sentinel Lymph Node Biopsy for Melanoma.
Sinnamon AJ; Song Y; Sharon CE; Yang YX; Elder DE; Zhang PJ; Xu X; Roses RE; Kelz RR; Fraker DL; Karakousis GC
Ann Surg Oncol; 2018 Nov; 25(12):3469-3475. PubMed ID: 30043316
[TBL] [Abstract][Full Text] [Related]
15. Comparison of Outcomes Between Surveillance Ultrasound and Completion Lymph Node Dissection in Children and Adolescents With Sentinel Lymph Node-Positive Cutaneous Melanoma.
Scoville SD; Stanek JR; Rinehardt H; Sutthatarn P; Abdelhafeez AH; Talbot LJ; Malek M; Leraas HJ; Tracy ET; Chen SY; Kim ES; Lotakis DM; Ehrlich PF; Favela JG; Le HD; Davidson J; Wilson CA; Seemann NM; Osman Y; Piche N; Hoang V; Petroze RT; Polites SF; McKay KG; Correa H; Lovvorn HN; Lee YM; Balagani A; Dasgupta R; Aldrink JH
Ann Surg; 2024 Mar; 279(3):536-541. PubMed ID: 37487006
[TBL] [Abstract][Full Text] [Related]
16. The analysis of the outcomes and factors related to iliac-obturator involvement in cutaneous melanoma patients after lymph node dissection due to positive sentinel lymph node biopsy or clinically detected inguinal metastases.
Zdzienicki M; Rutkowski P; Nowecki ZI; van Akkooi AC; Michej W; Dziewirski W; Świtaj T; Pieńkowski A; Sałamacha M; Bylina E; Eggermont AM
Eur J Surg Oncol; 2013 Mar; 39(3):304-10. PubMed ID: 23298828
[TBL] [Abstract][Full Text] [Related]
17. Sentinel node biopsy for early-stage melanoma: accuracy and morbidity in MSLT-I, an international multicenter trial.
Morton DL; Cochran AJ; Thompson JF; Elashoff R; Essner R; Glass EC; Mozzillo N; Nieweg OE; Roses DF; Hoekstra HJ; Karakousis CP; Reintgen DS; Coventry BJ; Wang HJ;
Ann Surg; 2005 Sep; 242(3):302-11; discussion 311-3. PubMed ID: 16135917
[TBL] [Abstract][Full Text] [Related]
18. Outcomes with adjuvant anti-PD-1 therapy in patients with sentinel lymph node-positive melanoma without completion lymph node dissection.
Eroglu Z; Broman KK; Thompson JF; Nijhuis A; Hieken TJ; Kottschade L; Farma JM; Hotz M; Deneve J; Fleming M; Bartlett EK; Sharma A; Dossett L; Hughes T; Gyorki DE; Downs J; Karakousis G; Song Y; Lee A; Berman RS; van Akkooi A; Stahlie E; Han D; Vetto J; Beasley G; Farrow NE; Hui JYC; Moncrieff M; Nobes J; Baecher K; Perez M; Lowe M; Ollila DW; Collichio FA; Bagge RO; Mattsson J; Kroon HM; Chai H; Teras J; Sun J; Carr MJ; Tandon A; Babacan NA; Kim Y; Naqvi M; Zager J; Khushalani NI
J Immunother Cancer; 2022 Aug; 10(8):. PubMed ID: 36002183
[TBL] [Abstract][Full Text] [Related]
19. The survival benefit to patients with positive sentinel node melanoma after completion lymph node dissection may be limited to the subgroup with a primary lesion Breslow thickness greater than 1.0 and less than or equal to 4 mm (pT2-pT3).
Nowecki ZI; Rutkowski P; Michej W
Ann Surg Oncol; 2008 Aug; 15(8):2223-34. PubMed ID: 18506535
[TBL] [Abstract][Full Text] [Related]
20. Nodal and systemic recurrence following observation of a positive sentinel lymph node in melanoma.
Bartlett EK; Lee AY; Spanheimer PM; Bello DM; Brady MS; Ariyan CE; Coit DG
Br J Surg; 2020 Oct; 107(11):1480-1488. PubMed ID: 32484242
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
